The Kansas City Business Journal has reported that Teva is in talks with Orlando, Florida-based biotech AssistRX to sell its Overland Park Patient Services & Solutions unit. The arm employs 200 people and provides support to patients with Parkinson’s disease and multiple sclerosis.
It has long been known that Teva is striving to consolidate its 7 US sites in order to cut costs. Teva’s Overland Park center, HQ for its Neuroscience segment and base for the Patient Service & Solutions unit, has already been targeted, by cutting 57 out of the total 388 jobs currently at the site. Over the years Teva has received a total of $53 million in incentives to concentrate its neuroscience activities in Overland. It will have to repay a portion of previous tax breaks if the total number of employees at the site is below 200 on February 29th, 2019.
(Source: Kansas City Business Journal)